nach oben

Current Rheumatology Reports

Erschienen in:

01.04.2013 | ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Valvular Heart Disease in Antiphospholipid Syndrome

verfasst von: Stéphane Zuily, Olivier Huttin, Shirine Mohamed, Pierre-Yves Marie, Christine Selton-Suty, Denis Wahl

Erschienen in: Current Rheumatology Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %. The definition is based on the presence of thickening or vegetation of the valves (mainly mitral and aortic) as described by Libman and Sacks for patients with systemic lupus erythematosus (SLE). Transthoracic and/or transoesophageal echocardiography (TTE and TEE, respectively) enable early and accurate diagnosis and help avoid misdiagnosis as rheumatic valve disease. The presence of antiphospholipid antibodies (aPL) in SLE patients is associated with a threefold greater risk of HVD, confirming the crucial importance of these antibodies in the pathogenic process, leading to thrombotic manifestations on valves because of hypercoagulability. Natural history is characterized by worsening of HVD over time with an increased risk for stroke. APS patients undergoing valve-replacement surgery are at high risk of thrombotic and bleeding complications. Thus aPL-associated HVD has affects clinical management of APS patients.

Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.PubMedCrossRef

Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737–40.PubMedCrossRef

Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64:1–10.PubMedCrossRef

• Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic Antiphospholipid Syndrome (APS) and non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20:165–73. This recent consensus report reviewed a large number of studies performed on patients with aPL and HVD and gave recommendations for management of these patients.PubMedCrossRef

Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.PubMedCrossRef

Menard GE. Establishing the diagnosis of Libman–Sacks endocarditis in systemic lupus erythematosus. J Gen Intern Med. 2008;23:883–6.PubMedCrossRef

Taguchi S, Hashimoto K, Sakamoto Y, Okuyama H, Ishii S. A case of mitral valve plasty for Libman–Sacks endocarditis mimicking a cardiac tumor. J Thorac Cardiovasc Surg. 2006;132:1465–7.PubMedCrossRef

Ford SE, Lillicrap D, Brunet D, Ford P. Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic ‘rheumatic type’ valvular heart disease. Arch Pathol Lab Med. 1989;113:350–3.PubMed

Espinola-Zavaleta N, Amigo MC, Vargas-Barron J, et al. Two- and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease. Lupus. 2001;10:511–3.PubMedCrossRef

10.

Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701–37.CrossRef

11.

Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985–2000. Mayo Clin Proc. 2001;76:1204–12.PubMedCrossRef

12.

Piette JC, Amoura Z, Papo T. Valvular heart disease and systemic lupus erythematosus. N Engl J Med. 1997;336:1324. author reply 1324–5.PubMedCrossRef

13.

Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918–25.PubMedCrossRef

14.

Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus. 2003;12:805–12.PubMedCrossRef

15.

Perez-Villa F, Font J, Azqueta M, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum. 2005;53:460–7.PubMedCrossRef

16.

Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95:1441–7.PubMedCrossRef

17.

Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology. 2007;108:331–7.PubMedCrossRef

18.

•• Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124:215–24. This meta-analysis of all available echocardiographic studies clearly demonstrated that for SLE patients with aPL, compared with those without, the risk of HVD, including Libman–Sacks endocarditis, was increased threefold.PubMedCrossRef

19.

Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke. 2005;36:592–6.PubMedCrossRef

20.

Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus. 2000;9:406–12.PubMedCrossRef

21.

Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005;96:574–9.PubMedCrossRef

22.

Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol. 2004;31:2402–7.PubMed

23.

Petri MA. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J Rheumatol. 2004;31:2329–30.PubMed

24.

Ziporen L, Goldberg I, Arad M, et al. Libman–Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996;5:196–205.PubMedCrossRef

25.

Blank M, Shani A, Goldberg I, et al. Libman–Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res. 2004;114:589–92.PubMedCrossRef

26.

Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Revisiting Libman–Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009;36:126–30.PubMedCrossRef

27.

Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92:714–5.PubMedCrossRef

28.

Liestol S, Sandset PM, Mowinckel MC, Wisloff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost. 2007;5:2204–10.PubMedCrossRef

29.

Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–87.PubMedCrossRef

30.

Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman–Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120:636–42.PubMedCrossRef

31.

Amoroso A, Cacciapaglia F, De Castro S, et al. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol. 2006;24:287–94.PubMed

32.

Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol. 2001;30:235–41.PubMedCrossRef

33.

• Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010;19:575–82. This study reports results from a relatively small cohort with a long follow-up and reports the incidence of new valvular involvement over time.PubMedCrossRef

34.

•• Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32. This study reported epidemiologic data of the largest multicenter cohort of APS patients ever published and reported results for HVD. However, because of the multicentre design the diagnostic workout was heterogeneous.PubMedCrossRef

35.

Tektonidou MG, Kampolis CF, Moyssakis I, et al. Myocardial dysfunction and valvulopathy worsens with time in patients with antiphospholipid syndrome: a 10-year follow-up study. [Abstract 1738]. Presented at the American College of Rheumatology / ARHP Annual Meeting. Washington, USA; November 10–14, 2012.

36.

Vinales KL, Gopalan RS, Lanza LA, Lester SJ, Chaliki HP. Unusual case of nonbacterial thrombotic endocarditis attributable to primary antiphospholipid syndrome. Circulation. 2010;122:e459–60.PubMedCrossRef

37.

Deo SV, Park SJ. Primary antiphospholipid antibody syndrome and Libmann–Sachs endocarditis. Mayo Clin Proc. 2011;86:929.PubMedCrossRef

38.

Shroff H, Benenstein R, Freedberg R, Mehl S, Saric M. Mitral valve Libman–Sacks endocarditis visualized by real time three-dimensional transesophageal echocardiography. Echocardiogr. 2012;29:E100–1.CrossRef

39.

Roldan CA. Diagnostic value of transesophageal echocardiography in Libman–Sacks endocarditis. Minerva Cardioangiol. 2009;57:467–81.PubMed

40.

Schneider C, Bahlmann E, Antz M, et al. Images in cardiovascular medicine. Unusual manifestation of Libman–Sacks endocarditis in systemic lupus erythematosus. Circulation. 2003;107:e202–4.PubMedCrossRef

41.

Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. J Clin Rheumatol. 2006;12:3–10.PubMedCrossRef

42.

Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490–3.PubMedCrossRef

43.

Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997;27:27–35.PubMedCrossRef

44.

Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12:518–23.PubMedCrossRef

45.

Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33:168–81.PubMedCrossRef

46.

•• Erdozain JG, Ruiz-Irastorza G, Segura MI, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64:1256–60. In this retrospective study of patients undergoing cardiac valve surgery, Erdozain et al. revealed the very high-risk of these procedures for patients with APS in terms of thrombotic and bleeding complications.

47.

Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127:414–20.PubMedCrossRef

48.

Colli A, Mestres CA, Espinosa G, et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37:154–8.PubMedCrossRef

49.

Hegde VA, Vivas Y, Shah H, et al. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome–a case-series. Heart Lung Circ. 2007;16:423–7.PubMedCrossRef

50.

Unger P, Plein D, Pradier O, LeClerc JL. Thrombosis of aortic valve homograft associated with lupus anticoagulant antibodies. Ann Thorac Surg. 2004;77:312–4.PubMedCrossRef

51.

Saito S, Ikeguchi H, Yamamoto H, Koike A, Yamaguchi K, Takeuchi E. Does antiphospholipid antibody syndrome affect bioprosthetic heart valve? midterm echocardiographic report. Jpn J Thorac Cardiovasc Surg. 2005;53:36–8.PubMedCrossRef

52.

Hogan WJ, McBane RD, Santrach PJ, et al. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc. 2000;75:971–6.PubMedCrossRef

53.

Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford). 2000;39:421–6.CrossRef

54.

Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705–15.PubMedCrossRef

55.

Maisano F, La Canna G, Colombo A, Alfieri O. The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique. J Am Coll Cardiol. 2011;58:2174–82.PubMedCrossRef

Titel: Valvular Heart Disease in Antiphospholipid Syndrome
verfasst von: Stéphane Zuily
Olivier Huttin
Shirine Mohamed
Pierre-Yves Marie
Christine Selton-Suty
Denis Wahl
Publikationsdatum: 01.04.2013
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 4/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-013-0320-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Arthritis Mutilans

Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV

Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?

Diagnosis and Management of Infectious Complications of Childhood Rheumatic Diseases